Thea Kalebic

2.1k citations

60 papers · 1.6k indexed · h-index 21

Impact in

Virology top 5%
- HIV Research and Treatment
Endocrinology, Diabetes and Metabolism top 5%
- Growth Hormone and Insulin-like Growth Factors

Papers in

Hematology 16
- Chronic Myeloid Leukemia Treatments 15
Genetics 14
- Chronic Lymphocytic Leukemia Research 13

Co-authors: Lee J. Helman Derek LeRoith A Meister Anthony S. Fauci Mary E. Anderson Audrey Kinter Guido Poli Vicky A. Blakesley
Journals: Blood (13 papers)Journal of Clinical Oncology (8 papers)Investigational New Drugs (3 papers)Cancer Research (3 papers)International Journal of Cancer (3 papers)
Partner nations: United States Italy Spain

In The Last Decade

Thea Kalebic

58 papers receiving 1.6k citations

Peers

Countries citing papers authored by Thea Kalebic

Since Specialization

Citations

This map shows the geographic impact of Thea Kalebic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thea Kalebic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thea Kalebic more than expected).

Fields of papers citing papers by Thea Kalebic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thea Kalebic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thea Kalebic. The network helps show where Thea Kalebic may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thea Kalebic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thea Kalebic Line = papers co-authored together Thea Kalebic links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers PLoS ONE ·Hadi Danaee, Thea Kalebic, Timothy Wyant, Matteo Fassan, Claudia Mescoli, Feng Gao, William L. Trepicchio, Massimo Rugge	2017	27
2	A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C Investigational New Drugs ·Khaldoun Almhanna, David Wright, T. Macarulla Mercadé, Jean‐Luc Van Laethem, Antonio Cubillo Gracián, Carmen Guillén‐Ponce, Jason E. Faris, Grigor'ev Ev, Richard Hubner, Johanna C. Bendell, Alain Bols, Jaime Feliú, Naureen Starling, Peter C. Enzinger, Mifthul Huda, Wells A. Messersmith, Huyuan Yang, Adedigbo A. Fasanmade, Hadi Danaee, Thea Kalebic	2017	31
3	TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study Cancer Research and Treatment ·Yung‐Jue Bang, Toshimi Takano, Chia‐Chi Lin, Adedigbo A. Fasanmade, Huyuan Yang, Hadi Danaee, Sebastian Saboune, Thea Kalebic, Hui Wang, Toshihiko Doi	2017	12
4	Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies Clinical Cancer Research ·Khaldoun Almhanna, Thea Kalebic, Cristina Cruz, Jason E. Faris, David P. Ryan, Anthony Pinedo, Tim Wyant, Adedigbo A. Fasanmade, Wells A. Messersmith, Jordi Rodón	2016	35
5	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies Investigational New Drugs ·David C. Smith, Thea Kalebic, Jeffrey R. Infante, Lillian L. Siu, Daniel M. Sullivan, Gordana Vlahovic, John Kauh, Feng Gao, Allison Berger, Stephen Tirrell, Neeraj Gupta, Alessandra Di Bacco, Deborah Berg, Guohui Liu, Jianchang Lin, Ai-Min Hui, John A. Thompson	2015	35
6	Mln0264, an Investigational, First-In-Class Antibody-Drug Conjugate Targeting Guanylyl Cyclase C (Gcc): First-In-Human Study in Patients with Advanced Gastrointestinal Malignancies Annals of Oncology ·Wells A. Messersmith, Khaldoun Almhanna, Jordi Rodón, Cristina Cruz, David P. Ryan, JungAh Jung, Adedigbo A. Fasanmade, Tim Wyant, Thea Kalebic	2013	2
7	c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells Molecular Cancer Research ·Antônio Porro, Nunzio Iraci, Simona Soverini, Daniel Diolaiti, Samuele Gherardi, Carolina Terragna, Sandra Durante, Emanuele Valli, Thea Kalebic, Roberto Bernardoni, 岡田義昭, Michelle Haber, Murray D. Norris, Michele Baccarani, Giovanni Martinelli, Giovanni Perini	2011	38
8	Inference of imatinib (IM) effects on leukemic stem cell (SC) compartment via mathematical modeling of IRIS treatment response data Journal of Clinical Oncology ·Dean Bottino, Ute Volbehr, Andrew M. Stein, Ani Georgieva, Jifeng Yu, Joseph Kahn, Gabriel Helmlinger, Thea Kalebic	2009	2
9	The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients. Blood ·Deborah L. White, Verity A Saunders, Thea Kalebic, Timothy P. Hughes	2008	6
10	Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation British Journal of Cancer ·Nathalie Voorzanger‐Rousselot, Елсуков Евгений Петрович, رحمت اله قاجار, Johann Zimmermann, Thea Kalebic, Patrick Garnero	2006	51
11	Epigenetic Changes: Potential Therapeutic Targets Annals of the New York Academy of Sciences ·Thea Kalebic	2003	27
12	Chemoprevention of Lung Cancer: New Directions Recent results in cancer research ·Éva Szabó, Thea Kalebic	2003	1
13	Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R International Journal of Cancer ·Thea Kalebic, Vicky A. Blakesley, Elizabeth E. Gleghorn, Sabine Plasschaert, Derek LeRoith, Lee J. Helman	1998	45
14	Role of the IGF-I receptor in mutagenesis and tumor promotion Journal of Endocrinology ·Vicky A. Blakesley, Bethel Stannard, Thea Kalebic, Lee J. Helman, Derek LeRoith	1997	64
15	Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor. Endocrinology ·Vicky A. Blakesley, Thea Kalebic, Lee J. Helman, Bethel Stannard, Teresa N. Faria, Charles T. Roberts, Derek LeRoith	1996	55
16	1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. The Journal of Clinical Endocrinology & Metabolism ·a la Pedagogía, Thea Kalebic, Mario Maggi, D. Marounek, John J. Letterio, Milan R. Uskoković, Lee J. Helman	1996	21
17	Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470 International Journal of Cancer ·Thea Kalebic, Maria Tsokos, Lee J. Helman	1996	17
18	In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. PubMed ·Thea Kalebic, Shunsuke Nagase, Lee J. Helman	1994	151
19	Organic Thiophosphate WR-151327 Suppresses Expression of HIV in Chronically Infected Cells AIDS Research and Human Retroviruses ·Thea Kalebic, Philip S. Schein	1994	9
20	Astrocyte-conditioned medium stimulates HIV-1 expression in a chronically infected promonocyte clone Journal of Neuroimmunology ·Ljubiša Vitković, Thea Kalebic, Busse, Ludwig, 1862-1907, Anthony S. Fauci	1990	31

About Thea Kalebic

Thea Kalebic is a scholar working on Hematology, Genetics, Virology, Oncology and Endocrinology, Diabetes and Metabolism, having authored 60 papers that have together received 1.6k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (13 papers), Colorectal Cancer Treatments and Studies (8 papers), Growth Hormone and Insulin-like Growth Factors (7 papers), HER2/EGFR in Cancer Research (7 papers), Sarcoma Diagnosis and Treatment (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Virology (116 citations), Endocrinology, Diabetes and Metabolism (332 citations), Cancer Research (238 citations), Oncology (424 citations) and Genetics (118 citations). Thea Kalebic has collaborated with scholars based in United States, Italy and Spain. Frequent co-authors include Lee J. Helman, Derek LeRoith, A Meister, Anthony S. Fauci, Mary E. Anderson, Audrey Kinter, Guido Poli, Vicky A. Blakesley, Derek LeRoith and Jeffrey A. Toretsky. Their work appears in journals such as Blood, Journal of Clinical Oncology, Investigational New Drugs, Cancer Research and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact